bioihbjkbjnl/mcl2 huggingface dataset:
Comparison of Two Different Treatment Methods
Condition: Subacromial Impingement Syndrome; Musculoskeletal Diseases; Musculoskeletal Injury; Musculoskeletal Pain; Weakness, Muscle
MeSH terms: Musculoskeletal Pain; Musculoskeletal Diseases; Shoulder Impingement Syndrome; Muscle Weakness; Syndrome; Rotator Cuff Injuries
Study type: Interventional

Summary: 
      A number of previous studies investigated the effects of kinesiotaping (KT) in subacromial
      impingement syndrome (SIS).
    

Detailed description: 
      Subacromial impingement syndrome (SIS) is characterized by shoulder pain that is exacerbated
      with especially arm elevation or overhead physical activities.
    

Intervention name(s): Kinesiotaping; Mulligan Mobilization Technique
Intervention type(s): Other; Other
Intervention description(s): KT was applied.; MMT was applied
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Randomized Controlled Trial
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Subacromial Impingement Syndrome; Mulligan Mobilization Technique; Kinesiotaping; Physiotherapy
Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
Condition: ADHD
MeSH terms: Attention Deficit Disorder with Hyperactivity
Study type: Interventional
Phase: Phase 4

Summary: 
      This study will consist of a six-week open-label treatment period with an extended duration
      methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large
      sample of youths aged 12-17 who meet Diagnostic and Statistical Manual of Mental Disorders,
      Fourth Edition (DSM-IV) criteria for ADHD.

      The researchers hypothesize that OROS MPH treatment will be associated with low rates of
      cigarette smoking in ADHD youth.
    


Intervention name(s): methylphenidate HCl (Concerta)
Intervention type(s): Drug
Intervention description(s): OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
Other intervention name(s): Concerta
Intervention MeSH terms: Methylphenidate
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: cigarette smoking; ADHD; adolescents; Concerta
Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants
Condition: Healthy Volunteers
Study type: Interventional
Phase: Phase 1

Summary: 
      The primary objective of this study is to investigate the rate and routes of excretion,
      including the mass balance, after single oral dose administration of DC-806 containing 3.7
      MBq (100 μCi) of [14C]-DC-806 in urine and feces.
    


Intervention name(s): DC-806; [14C]-DC-806
Intervention type(s): Drug; Drug
Intervention description(s): Oral tablets; Oral capsules
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Keywords: DC-806; Mass Balance
A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant
Condition: Fungal Infections
MeSH terms: Mycoses
Study type: Interventional
Phase: Phase 1

Summary: 
      The study will evaluate PK and safety of two dose levels of Micafungin (FK463) as Antifungal
      prophylaxis in children and adolescents undergoing HSCT
    

Detailed description: 
      This is a prospective, multi-center, open-label, repeat-dose pharmacokinetic study that
      contains two treatment (micafungin 1.0mg/kg and 1.5mg/kg) dose groups. Subjects will be
      enrolled according to age and stratified by weight to receive either 1.0mg/kg (weight > 25kg)
      or 1.5mg/kg ( weight < 25kg) micafungin.

      Children (4 months to < 2years, 2 to 5 years and 6 to 11 years) and adolescents (12 to 16
      years) undergoing HSCT who require antifungal prophylaxis will be enrolled
    

Intervention name(s): Micafungin
Intervention type(s): Drug
Intervention description(s): IV
Other intervention name(s): FK463
Intervention MeSH terms: Micafungin
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Antifungal Prophylaxis; Hematopoietic Stem Cell Transplant; HSCT; Micafungin
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Study type: Interventional
Phase: Phase 1

Summary: 
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have
      advanced solid tumors that have not responded to previous therapy.
    

Detailed description: 
      OBJECTIVES: I. Determine the maximum tolerated dose, dose limiting toxicities, safety, and a
      recommended phase II dose of BMS-247550 administered as a 1 hour infusion every 3 weeks in
      patients with advanced solid tumors. II. Evaluate the plasma pharmacokinetics of this drug in
      this patient population. III. Determine any preliminary evidence of antitumor activity of
      this drug in these patients.

      OUTLINE: This is a dose escalation study. Patients receive BMS-247550 IV over 1 hour every 3
      weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity
      or disease progression. Cohorts of 3-6 patients receive escalating doses of BMS-247550 until
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that
      at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities. Patients are followed
      every 3 months until death.

      PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study within 8-12
      months.
    

Intervention name(s): ixabepilone
Intervention type(s): Drug
Primary purpose: Treatment
Keywords: unspecified adult solid tumor, protocol specific
Priming Through Timing. Using Opposing Strategies to Enhance Motor Learning for Individuals With Parkinson's Disease
Condition: Parkinson Disease
MeSH terms: Parkinson Disease
Study type: Interventional

Summary: 
      The purpose of this study is to determine how using auditory cues of a metronome at various
      frequencies impacts the gait mechanics and balance in people with Parkinson's disease when
      walking over ground and on a treadmill. We will enroll 10 participants with a diagnosis of
      Parkinson's disease (Stages 2 or 3). All participants will complete 18 training sessions over
      6 weeks and participate in pre- and post-testing of gait and balance.
    


Intervention name(s): Rhythmic Auditory Stimulation
Intervention type(s): Other
Intervention description(s): Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: gait; balance; auditory cues
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Condition: Polycystic Kidney, Autosomal Recessive
MeSH terms: Kidney Diseases; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive
Study type: Interventional
Phase: Phase 1

Summary: 
      This study evaluates safety and tolerability of a single ascending dose of a tesevatinib
      liquid formulation administered to pediatric subjects with ARPKD.
    

Detailed description: 
      This study is a phase 1 clinical trial focused on evaluating safety and tolerability of the
      Tesevatinib study drug, which is an oral solution at a 15mg/mL concentration.

      To determine safety of the tesevatinib liquid formulation in pediatric subjects (age 5-12)
      with ARPKD, all participants receive active study drug on Day 1 of the study enrollment. To
      evaluate plasma pharmacokinetics (PK) of the single dose of tesevatinib in the ARPKD
      pediatric subjects, the blood for PK sampling is drawn on Day 1, 2, and 3 of the study.
      Tesevatinib dosing will be followed by a PK and a 2-week safety evaluation. After the
      completion of the safety review subjects may continue onto the next dosing group at the
      discretion of the investigator and the medical monitor.

      There are three dosing arms in this study. Six participants will enroll into first dosing
      cohort (0.25mg/kg). Participants may be enrolled in two subsequent cohorts with increased
      dose (0.5mg/kg and 1.0mg/kg), if safety reporting is favorable.

      Medical history will be taken at Screening Visit. Echocardiogram will be performed at
      Screening and Day 14. Subjects will undergo audiology testing, as well as ocular monitoring
      at Screening and Day 14. Blood will be drawn for a panel of laboratory tests.
    

Intervention name(s): Tesevatinib
Intervention type(s): Drug
Intervention description(s): One dose of the study drug in liquid form
Other intervention name(s): KD019
Intervention MeSH terms: XL647
Allocation: Non-Randomized
Intervention model: Sequential Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: ARPKD; Autosomal Recessive Polycystic Kidney Disease; Pediatric Polycystic Kidney; Tesevatinib; Polycystic Kidney Disease
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
Condition: Interstitial Pulmonary Fibrosis ARDS; COPD (Chronic Obstructive Pulmonary Disease); Bronchiectasis; Lymphangioleiomyomatosis; Primary Pulmonary Hypertension; ARDS (Acute Respiratory Distress Syndrome)
MeSH terms: Lymphangioleiomyomatosis; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Hypertension, Pulmonary; Acute Lung Injury; Pulmonary Fibrosis; Bronchiectasis; Familial Primary Pulmonary Hypertension; Pulmonary Arterial Hypertension
Study type: Interventional

Summary: 
      ECMO(Extracorporeal membrane oxygenation) is being essential for cardiopulmonary failure
      patients. There are two types of ECMO, which is veno-veno (V-V) that can be used in
      respiratory failure patients and veno-arterial (V-A) that can be used in cardiac failure
      patients. V-A ECMO can also be used during lung transplantation, substitution of
      cardiopulmonary bypass, which can show sufficient performance during operation and better
      postoperative outcome. However, regarding V-A ECMO circulating from femoral vein to femoral
      artery, there is a pro blem of differential hypoxia which might influence coronary artery and
      head vessels. In this prospective study, the investigators are planning to put another ECMO
      catheter into internal jugular vein which takes a role of left to right shunt, to mitigate
      the hypoxia of coronary artery.
    


Intervention name(s): Veno-veno-arterial ECMO
Intervention type(s): Procedure
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Tolerability and Satisfaction With Evie
Condition: Infertility
MeSH terms: Infertility
Study type: Interventional

Summary: 
      The purpose of this study is to determine patient satisfaction and tolerability of the Evie®
      slow-release insemination device for US population. Additionally, to assess cramping with the
      device and to determine pregnancy rates using the slow insemination device compared to
      standard IUI.
    


Intervention name(s): Evie Slow-release Insemination Device; Traditional Intrauterine Insemination
Intervention type(s): Device; Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Diagnostic
Keywords: Infertility; Intrauterine Insemination; Slow-release Insemination; Evie
Comparison of Effects of PEEP Levels on Respiratory Mechanics in Patients Undergoing Laparoscopic Cholecystectomy
Condition: Respiratory System Abnormalities
MeSH terms: Respiratory System Abnormalities
Study type: Observational [Patient Registry]

Summary: 
      Laparoscopic cholecystectomy is accepted as gold standard in the management of
      cholelithiasis. Although laparoscopic procedures have many advantages,intra-abdominal CO2
      insufflation can cause decreased lung volumes and compliance, increased airway resistance and
      impaired ventilation-perfusion ratio. In this study, investigators aim to investigate effects
      of intra-operative PEEP treatment at 3 distinct levels on respiratory dynamics and
      elimination time of volatile anesthetic agent.
    

Detailed description: 
      In the study, 75 ASA I-II patients aged 30-65 years will be randomized into 3 groups to
      receive 0 cmH2O PEEP (Group-1), 5 cmH2O PEEP (Group-2) and 8 cmH2O PEEP (Group-3) in PVC
      mode. In all patients underwent general anesthesia; hemodynamic parameters, Ppeak, Pplateau,
      compliance values as well as Fisevo/Fexpsevo ratio at 1 MAC and times from 1 MAC to 0.3 and
      0.1 MAC will be recorded. In addition, preoperative and postoperative pulmonary function
      tests will be compared in all patients.
    

Intervention name(s): PEEP 0; PEEP 5; PEEP 8
Intervention type(s): Procedure; Procedure; Procedure
Intervention description(s): 0 cmH2O positive end expiratory pressure; 5 cmH2O positive end expiratory pressure; 8 cmH2O positive end expiratory pressure
Observational model: Case-Crossover
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        patients who will undergo for elective laparoscopic cholecystectomy
      
Keywords: PEEP; compliance; peak airway pressures
Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications
Condition: Type 2 Diabetes
MeSH terms: Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 4

Summary: 
      Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide-1 (GLP-1) mimetics or
      analogs, which rely on the gastrointestinal hormones that are part of the incretin system for
      the treatment of T2DM, provide a therapeutic alternative to common oral antihyperglycemic
      agents (eg, sulfonylureas, thiazolidinediones). Although GLP-1 analogs and DPP-4 inhibitor
      medications are effective, there are differences between these products, including method of
      administration (injectable versus oral). Previous studies have shown that patients prefer
      additional oral agents over injectable agents because of fear of injections and the desire to
      avoid them. Patient preference is both clinically and financially important, as it can have
      long-term implications in terms of patients' motivation and insight into their disease state
      and its treatment, which might have a direct impact on the patient's compliance and treatment
      adherence. The aim of the current study is to evaluate the proportion of T2DM patients
      preferring oral anti-diabetic treatment with vildagliptin + metformin versus an injectable
      anti-diabetic treatment with liraglutide after 4 weeks of treatment with each medication.
    


Intervention name(s): Vildagliptin/ Metformin; Liraglutide; Metformin
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Single pill combination of Vildagliptin/ Metformin (50/1000 mg).; 1.2 mg once daily by commercially available injection pens; 1000 mg tablets twice daily
Intervention MeSH terms: Metformin; Liraglutide; Vildagliptin
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: patient preference; vildagliptin; liraglutide
NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy
Condition: Xerostomia
MeSH terms: Xerostomia; Sleep Apnea Syndromes
Study type: Interventional

Summary: 
      To assess whether the daily use of NeutraSal will prevent or reduce dry mouth in patients
      undergoing CPAP therapy for OSAS and improve CPAP compliance
    

Detailed description: 
      Subjects diagnosed with Obstructive Sleep Apnea Syndrome (OSAS) who have started CPAP
      treatment and have complained of dry mouth or developed worsening of a pre-existing dry mouth
      as an effect of CPAP treatment will test the effectiveness of NeutraSal mouthwash in
      preventing or reducing his/her dry mouth perceptions and improving their compliance with
      CPAP.
    

Intervention name(s): NeutraSal; Placebo Comparator
Intervention type(s): Drug; Drug
Intervention description(s): NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.; Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Prevention
Keywords: Obstructive Sleep Apnea Syndrome
Effect of Head Elevation on LMA Insertion
Condition: Laryngeal Masks; Urinary Bladder Neoplasms
MeSH terms: Urinary Bladder Neoplasms
Study type: Interventional

Summary: 
      The purpose of this study is to compare the first attempt success rate of laryngeal mask
      airway insertion according to the degree of head elevation.
    

Detailed description: 
      The purpose of this study is to compare the first attempt success rate of laryngeal mask
      airway insertion between 7 cm head elevation and 14 cm head elevation in patients who
      undergoing transurethral bladder tumor resection.
    

Intervention name(s): Laryngeal mask airway insertion
Intervention type(s): Procedure
Intervention description(s): Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Other
VR Usage in Non-Invasive Surgical Sub-Specialty Procedures
Condition: Stress, Emotional; Stress, Psychological; Behavioral Symptoms
MeSH terms: Stress, Psychological; Behavioral Symptoms
Study type: Interventional

Summary: 
      Preprocedural, preoperative, and prevascular access anxiety in pediatric patients has been
      previously shown to increase the likelihood of family stressors, agitation, sleep
      disturbances, and negative behavioral changes. The purpose of this study is to determine if a
      non-invasive distracting device (Virtual Reality (VR) headset, Augmented Reality (AR)
      headset, or bed mounted Video Projection unit (i.e. BERT, Bedside EnterRtainment Theater)) is
      more effective than the standard of care (i.e., no technology based distraction) for
      preventing anxiety before non-invasive surgical sub-specialty procedures among children
      during out-patient clinic visits. Examples of the most common procedures include, but are not
      limited to gastrostomy tube exchanges, suture removals, dressing changes, foley insertions,
      EEG set up, chest tube removals, cast removals, pin removals and other similar procedures.
      (The investigators refer to these procedures under an umbrella term of non-invasive surgical
      subspecialty procedures). The anticipated primary outcome will be reduction of child's
      anxiety during and after procedures.
    

Detailed description: 
      Anxiety among children undergoing non-invasive surgical subspecialty procedures is common.
      Not only is high anxiety traumatic, but research in a surgical setting indicates that high
      anxiety in children before surgery leads to adverse outcomes such as increased pain and
      analgesics requirements, delayed hospital discharge and maladaptive behavioral changes.
      Treating anxiety may decrease any of these undesirable behaviors that may arise when
      experiencing a non-invasive surgical subspecialty procedure in a clinical setting.

      In this study, investigators hope to determine if technology based distractions (VR headsets
      with headphones, AR headset, or BERT projector) are more effective than standard care for
      preventing high anxiety before non-invasive surgical subspecialty procedures. As a secondary
      objective of the study, the investigators seek to determine if the use of technology based
      distraction will result in higher parent and patient satisfaction as well as evaluate which
      techniques are most effective. As a tertiary aim, the investigators seek to understand if
      passive or active interventions are more effective in decreasing anxiety.
    

Intervention name(s): Technology Based Distractions
Intervention type(s): Behavioral
Intervention description(s): Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Prevention
A Randomised Trial of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression
Condition: Depression; Anxiety
MeSH terms: Depression, Postpartum; Depression; Depressive Disorder
Study type: Interventional
Phase: Phase 3

Summary: 
      Th purpose of this study is to determine whether dual psychological and pharmacological
      treatment is superior to either mono-therapy alone in the treatment of postnatal depression.
    


Intervention name(s): Sertraline; Cognitive Behavioural Therapy
Intervention type(s): Drug; Behavioral
Intervention MeSH terms: Sertraline
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment